Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512275 | 0.94 | CTSK (0.48) | CTSKPRMT5WDR77CTSLCTSS | |
| SCHEMBL6990329 | 0.93 | CTSK (0.43) | CTSKPRMT5WDR77CTSLCTSS | |
| SCHEMBL6510130 | 0.91 | CTSK (0.51) | CTSKPRMT5WDR77EPHX2 | |
| SCHEMBL6523396 | 0.91 | CTSK (0.52) | CTSKCTSLCTSS | |
| SCHEMBL5743413 | 0.87 | CTSK (0.45) | CTSKPRMT5WDR77CTSLCTSS | |
| SCHEMBL6514508 | 0.85 | CTSK (0.53) | CTSKCTSLCTSS | |
| SCHEMBL6511685 | 0.85 | CTSK (0.51) | CTSKCTSLCTSS | |
| SCHEMBL6515480 | 0.82 | CTSK (0.49) | CTSKCTSLCTSS | |
| SCHEMBL6518424 | 0.82 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL6515438 | 0.82 | CTSK (0.49) | CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | CTSK 4/4885PRMT5 2569/4885WDR77 4213/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | CTSK 5/4885PRMT5 2059/4885WDR77 4317/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | CTSK 3/4885PRMT5 1991/4885WDR77 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.